Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists

J Med Chem. 2022 Oct 13;65(19):12956-12969. doi: 10.1021/acs.jmedchem.2c00793. Epub 2022 Sep 27.

Abstract

In this work, cysteine staples were used as a late-stage functionalization strategy to diversify peptides and build conjugates targeting the melanocortin G-protein-coupled receptors [melanocortin receptor-1 (MC1R) and MC3R-MC5R]. Monocyclic and bicyclic agonists based on sunflower trypsin inhibitor-1 were used to generate a selection of stapled peptides that were evaluated for binding (pKi) and functional activation (pEC50) of the melanocortin receptor subtypes. Stapled peptides generally had improved activity, with aromatic stapled peptides yielding selective MC1R agonists, including a xylene-stapled peptide (2) with an EC50 of 1.9 nM for MC1R and >150-fold selectivity for MC3R and MC4R. Selected stapled peptides were further functionalized with linkers and payloads, generating a series of conjugated peptides with potent MC1R activity, including one pyridazine-functionalized peptide (21) with picomolar activity at MC1R (Ki 58 pM; EC50 < 9 pM). This work demonstrates that staples can be used as modular synthetic tools to tune potency and selectivity in peptide-based drug design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cysteine
  • Melanocortins
  • Peptides / pharmacology
  • Pyridazines*
  • Receptor, Melanocortin, Type 1* / agonists
  • Receptor, Melanocortin, Type 3
  • Receptor, Melanocortin, Type 4
  • Receptors, Melanocortin / metabolism
  • Structure-Activity Relationship
  • Xylenes

Substances

  • Melanocortins
  • Peptides
  • Pyridazines
  • Receptor, Melanocortin, Type 1
  • Receptor, Melanocortin, Type 3
  • Receptor, Melanocortin, Type 4
  • Receptors, Melanocortin
  • Xylenes
  • Cysteine